These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28958372)

  • 1. Practical aspects of immunoglobulin replacement.
    Ballow M
    Ann Allergy Asthma Immunol; 2017 Oct; 119(4):299-303. PubMed ID: 28958372
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved IgG3 levels and reduced infection rate in a woman with CVID switched from intravenous to subcutaneous immunoglobulin therapy.
    Shapiro RS
    Immunotherapy; 2012 Dec; 4(12):1835-9. PubMed ID: 23240751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration.
    Quinti I; Soresina A; Agostini C; Spadaro G; Matucci A; Sfika I; Martini H; Borghese F; Guerra A; Alessandra V; Visentini M; Plebani A; Fiorilli M
    J Clin Immunol; 2008 May; 28(3):263-7. PubMed ID: 18214651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute renal dysfunction caused by nonsucrose intravenous immunoglobulin in common variable immunodeficiency.
    Kim AS; Broide DH
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):231-233. PubMed ID: 28024991
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.
    Wasserman RL; Melamed I; Nelson RP; Knutsen AP; Fasano MB; Stein MR; Rojavin MA; Church JA
    Clin Pharmacokinet; 2011 Jun; 50(6):405-14. PubMed ID: 21553933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granuloma-like lesion at subcutaneous immunoglobulin site in a common variable immunodeficiency patient.
    Gupta A; Wang B; Gupta S
    Immunotherapy; 2019 Oct; 11(14):1177-1180. PubMed ID: 31478429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 35-Year-Old Man With Episodic Fever and Cough.
    Lewis KL; Patel S; Valery J
    Mayo Clin Proc; 2018 Dec; 93(12):1848-1852. PubMed ID: 30414731
    [No Abstract]   [Full Text] [Related]  

  • 8. Potential Anti-Tumor Activity of Intravenous and Subcutaneous Immunoglobulin.
    Danieli MG; Gelardi C; Pedini V; Gabrielli A
    Isr Med Assoc J; 2018 Dec; 20(12):782-783. PubMed ID: 30550011
    [No Abstract]   [Full Text] [Related]  

  • 9. Dysregulated CD1 profile in myeloid dendritic cells in CVID is normalized by IVIg treatment.
    Paquin-Proulx D; Santos BA; Carvalho KI; Toledo-Barros M; Oliveira AK; Kokron CM; Kalil J; Moll M; Kallas EG; Sandberg JK
    Blood; 2013 Jun; 121(24):4963-4. PubMed ID: 23766460
    [No Abstract]   [Full Text] [Related]  

  • 10. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin.
    Radinsky S; Bonagura VR
    J Allergy Clin Immunol; 2003 Sep; 112(3):630-3. PubMed ID: 13679829
    [No Abstract]   [Full Text] [Related]  

  • 11. Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin.
    Markvardsen LH; Christiansen I; Andersen H; Jakobsen J
    Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):409-12. PubMed ID: 26096187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin (IVIG) efficiency in women with common variable immunodeficiency (CVID) decreases significantly during pregnancy.
    Egawa M; Kanegane H; Imai K; Morio T; Miyasaka N
    J Matern Fetal Neonatal Med; 2019 Sep; 32(18):3092-3096. PubMed ID: 29614902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously.
    Desai SH; Chouksey A; Poll J; Berger M
    J Allergy Clin Immunol; 2009 Oct; 124(4):854-6. PubMed ID: 19767071
    [No Abstract]   [Full Text] [Related]  

  • 15. A recipient of immunoglobulin from a donor who developed vCJD.
    El-Shanawany T; Jolles S; Unsworth DJ; Williams P
    Vox Sang; 2009 Apr; 96(3):270. PubMed ID: 19522885
    [No Abstract]   [Full Text] [Related]  

  • 16. [Immunoglobulin therapy of primary humoral immunologic deficiencies].
    Bordigoni P
    Rev Prat; 2007 Oct; 57(15):1691-8. PubMed ID: 18080428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administering intravenous immunoglobulin during infection is associated with infusion reactions in selected patients.
    Khan S; Abuzakouk M; Doré PC; Sewell WA
    Ir J Med Sci; 2011 Mar; 180(1):125-8. PubMed ID: 21136195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful use of 20% subcutaneous immunoglobulin in pregnant women with primary immune deficiency.
    Duff C; Krishnaswamy G; Ghably J
    Ann Allergy Asthma Immunol; 2016 Jan; 116(1):83-5. PubMed ID: 26707772
    [No Abstract]   [Full Text] [Related]  

  • 19. Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.
    Berger M; Cunningham-Rundles C; Bonilla FA; Melamed I; Bichler J; Zenker O; Ballow M
    J Clin Immunol; 2007 Sep; 27(5):503-9. PubMed ID: 17479360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common variable immune deficiency and treatment with intravenous immunoglobulin during pregnancy.
    Brinker KA; Silk HJ
    Ann Allergy Asthma Immunol; 2012 Jun; 108(6):464-5. PubMed ID: 22626605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.